An Open Label, Single Group Assigned, Multicenter Study of Apatinib in Patients With Chemo-refractory Advanced or Metastatic Adenocarcinoma of Stomach or Gastroesophageal Junction
Phase of Trial: Phase IV
Latest Information Update: 20 Apr 2016
At a glance
- Drugs Apatinib (Primary)
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
- Focus Adverse reactions
- Sponsors Jiangsu Hengrui Medicine Co.
- 18 Apr 2016 Status changed from active, no longer recruiting to recruiting.
- 30 Apr 2015 New trial record